GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease

Publisher： Karger

E-ISSN： 1423-0216|24|1|60-66

ISSN： 1021-7401

Source： Neuroimmunomodulation, Vol.24, Iss.1, 2017-08, pp. : 60-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gender Differences in Methamphetamine-Induced mRNA Associated with Neurodegeneration in the Mouse Nigrostriatal Dopaminergic System

By  

Neuroendocrinology, Vol. 77, Iss. 4, 2003-05 ,pp. : 232-238

Karger

Access to resources Recommend Favorite

GPER1 Stimulation Alters Posttranslational Modification of RGSz1 and Induces Desensitization of 5-HT1A Receptor Signaling in the Rat Hypothalamus

By  

Neuroendocrinology, Vol. 100, Iss. 2-3, 2014-11 ,pp. : 228-239

Karger

Access to resources Recommend Favorite

Serum Levels of Chemokines in Parkinson’s Disease

By  

Neuroimmunomodulation, Vol. 18, Iss. 4, 2011-03 ,pp. : 240-244

Karger

Access to resources Recommend Favorite

Evolutionary Conservation of 3-Iodothyronamine as an Agonist at the Trace Amine-Associated Receptor 1

By  

European Thyroid Journal, Vol. 4, Iss. 1, 2015-05 ,pp. : 9-20

Karger

Access to resources Recommend Favorite

Influence of Age and Gender on Cytokine Expression in a Murine Model of Parkinson’s Disease

By  

Neuroimmunomodulation, Vol. 14, Iss. 5, 2008-01 ,pp. : 255-265

Karger

Access to resources Recommend Favorite